Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaGünter U. Höglinger, Keith A. Josephs, Anthony E. Lang et al.|Movement Disorders|2017Cited by 2.3k
Which ante mortem clinical features predict progressive supranuclear palsy pathology?Gesine Respondek, Carolin Kurz, Thomas Arzberger et al.|Movement Disorders|2017Cited by 163
Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trialJohannes Levin, Johannes Schwarz, Sylvia Maaß et al.|The Lancet Neurology|2019Cited by 126